2049127-88-8

Basic information

• Product Name: (R)-Benzyl 2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride
• Synonyms: (R)-Benzyl 2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride;benzyl (R)-2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride
• CAS NO: 2049127-88-8
• Molecular Formula: C17H20ClNO4S
• Molecular Weight: 369.863
• Mol File: 2049127-88-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (R)-Benzyl 2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Benzyl 2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride(2049127-88-8)
• EPA Substance Registry System: (R)-Benzyl 2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride(2049127-88-8)

Safety Data

• Hazardous Substances Data: 2049127-88-8(Hazardous Substances Data)

Usage

General Description

The chemical "(R)-Benzyl 2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride" is a compound containing a benzyl group, an amino group, and a propanoate group, all connected to form a single molecule. The addition of a hydrochloride group makes this compound a salt, which is commonly used in pharmaceuticals for its potential biological activity. The presence of a methylsulfonyl group suggests that this compound may have potential for use as a sulfonylating agent or as a precursor to other compounds containing the sulfonyl functional group. Overall, this compound has the potential to be used in various chemical and pharmaceutical applications due to its unique structure and potential reactivity.

Upstream product

• 34896-80-5 1-bromo-3-methanesulphonylbenzene 
• 108957-20-6 (R)-N-(tert-butoxycarbonyl)-3-iodoalanine benzyl ester 
• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 
• 1289646-78-1 (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate 
• 1289646-76-9 (S)-2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propanol 
• 82278-73-7 (2S)-3-(3-bromophenyl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 

Downstream Products

• 1194550-61-2 benzyl (S)-2-[2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido]-3-[3-(methylsulfonyl)phenyl]propanoate 

Relevant articles and documents

Preparation method of lifitegrast intermediate

The invention relates to a preparation method of a lifitegrast intermediate. The preparation method is implemented by the following route, has the advantages of short synthesis route, high yield and high safety, and is simple and convenient to operate and suitable for industrial production. According to the preparation method, a compound II reacts with metal zinc in an organic solvent to generatean organic zinc reagent, a compound I carries out a coupling reaction with the organic zinc reagent, a palladium reagent and a phosphorus ligand to obtain a compound III, and Boc protecting groups ofthe compound III are removed to obtain a compound IV, wherein R1 and R2 groups are respectively and independently selected from methyl, ethyl, vinyl, n-propyl, isopropyl, propenyl, propynyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, butenyl, cyclobutyl, n-pentyl, iso-pentyl, cyclopentyl, n-hexyl, cyclohexyl, phenyl and benzyl.

Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye

LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.